MDCO The Medicines Company

-1.6  -5%
Previous Close 35.36
Open 33.3
Price To Book -33.1
Market Cap 2,494,855,526
Shares 73,899,749
Volume 2,017,392
Short Ratio
Av. Daily Volume 1,336,654

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data 3Q 2019.
Inclisiran - ORION-9
Development discontinued due to poor effiacy - November 7, 2016.
Acute coronary syndrome (ACS)
Approved August 29, 2017.
Complicated urinary tract infections (cUTI)
CRL April 30 2014. Approved June 22 2015
Reduction of thrombotic cardiovascular events including stent thrombosis in patients with coronary artery disease undergoing percutaneous coronary intervention (PCI)
Approved April 30, 2015.
Acute postoperative pain
Approved August 6 2014 under priority review.
Phase 3 trial to be initiated 1H 2018.
Homozygous familial hypercholesterolemia (HoFH)
Phase 3 sata due 3Q 2019.
Inclisiran - ORION-10
Cardiovascular disease (ASCVD)
Phase 3 data due 3Q 2019.
Inclisiran - ORION 11
Cardiovascular disease (ASCVD)
Phase 2 open-label data presented May 18, 2019. 51% decrease in LDL-C levels.
Inclisiran - ORION 3
Cardiovascular disease (ASCVD)

Latest News

  1. The Daily Biotech Pulse: Genfit NASH Drug In China, Conatus Explores Sale, Gilead Stitches Up Immuno-Oncology Partnership
  2. The Medicines Company Announces Launch of Public Offering of Common Stock
  3. Alnylam Completes Enrollment in Phase III Study of Lumasiran
  4. See what the IHS Markit Score report has to say about Medicines Co.
  5. Did Hedge Funds Drop The Ball On Medicines Company (MDCO)?
  6. Signal Says This Drug Stock Isn't Done Climbing
  7. Alnylam Completes Rolling NDA Submission to FDA for Givosiran
  8. These Bullish Medicines Company Options Trades Suggest More Upside Could Be Coming
  9. Options Traders Expect Huge Moves in Medicines Company (MDCO) Stock
  10. Alnylam Initiates Phase I Study on Hypertension Candidate
  11. Notable Insider Buys This Past Week: Coty, Zillow and More
  12. The Medicines Company Presents Clinical Data Analyses for Inclisiran at 87th European Atherosclerosis Society Congress
  13. Medicines Co. (MDCO) Up 17.1% Since Last Earnings Report: Can It Continue?
  14. Medicines Company Rallies On Positive LDL Cholesterol Study Results
  15. SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating The Medicines Company for Potential Breaches Of Fiduciary Duty By Its Board of Directors
  16. New Long-Term Data Show that Twice-a-Year Dosing with Inclisiran Results in Persistent Lowering of LDL Cholesterol with No Material Safety Observations Out to Three Years
  17. What Kind Of Share Price Volatility Should You Expect For The Medicines Company (NASDAQ:MDCO)?